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Abstract
The southern cattle fever tick, Rhipicephalus (Boophilus) microplus, is no doubt the most economically important 
ectoparasite of cattle globally. The inappropriate use of chemical acaricides has driven the evolution of resistance in 
populations of R. (B.) microplus. Anti-tick vaccines represent a technology that can be combined with acaricides in 
integrated control programs to mitigate the impact of R. (B.) microplus. The recombinant form of Bm86 antigen from 
the Campo Grande (rBm86-CG) strain of R. (B.) microplus was produced using the Pichia pastoris expression system 
to test its ability to immunoprotect cattle against tick infestation. Secretion of rBm86-CG by P. pastoris through the 
bioprocess reported here simplified purification of the antigen. A specific humoral immune response was detected by 
ELISA in vaccinated cattle. Immunoblot results revealed that polyclonal antibodies from vaccinated cattle recognized 
a protein in larval extracts with a molecular weight corresponding to Bm86. The rBm86-CG antigen showed 31% 
efficacy against the Campo Grande strain of R. (B.) microplus infesting vaccinated cattle. The rBm86-CG is an antigen 
that could be used in a polyvalent vaccine as part of an integrated program for the control of R. (B.) microplus in the 
region that includes Mato Grosso do Sul.
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Resumo
O carrapato Rhipicephalus (Boophilus) microplus é, sem dúvidas, o ectoparasito economicamente mais importante 
para o gado a nível mundial. A utilização inadequada de acaricidas tem impulsionado a evolução da resistência em 
populações de R. (B.) microplus. Vacinas contra o carrapato representam uma tecnologia que pode ser combinada com 
acaricidas em programas de controle integrado para diminuir o impacto de R. (B.) microplus. A forma recombinante 
da Bm86 da cepa Campo Grande (rBm86-CG) de R. (B.) microplus foi produzido utilizando o sistema de expressão 
em Pichia pastoris para testar sua capacidade de imunoproteção ao gado contra a infestação de carrapatos. A secreção 
de rBm86-CG em P. pastoris através do bioprocesso relatado simplificou a purificação do antígeno. A resposta 
imune humoral específica foi detectada por ELISA em bovinos vacinados. Resultados de imunoblot revelaram que 
anticorpos policlonais de bovinos vacinados reconheceram uma proteína em extratos de larvas com um peso molecular 
correspondente à Bm86. O antígeno rBm86-CG mostrou eficácia de 31% contra a cepa CG de R. (B.) microplus 
utilizada para infestar os bovinos vacinados. Pelos resultados obtidos, concluímos que a rBm86-CG é um antígeno que 
pode ser usado em uma vacina polivalente, como parte de um programa integrado para o controle de R. (B.) microplus 
no estado do Mato Grosso do Sul, Brasil.
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Introduction
Rhipicephalus (B.) microplus, commonly known as the southern 
cattle fever tick, is arguably the most economically important 
ectoparasite of livestock in tropical and subtropical regions of 
the world. Chemical acaricides are readily available to ranchers 
for the control of R. (B.) microplus infesting cattle. The utility 
of chemical acaricides has been hampered by inappropriate use, 
which has driven the evolution of acaricide resistance among R. 
(B.) microplus populations (FURLONG, 2004). Vaccines provide 
an alternative tool for tick control (WILLADSEN; JONGEJAN, 
1999). Integrated tick control programs that include vaccines can 
reduce the use of chemical acaricides, lower the cost of animal 
production, mitigate environmental contamination impacts, and 
decrease the risk of chemical residues in animal-derived products 
(DE LA FUENTE et al., 1998; GARCÍA-GARCÍA et al., 2000; 
REDONDO et al., 1999).
TickGardPLUS (Intervet Australia Pty. Ltd., 91-105 Harpin 
Street, Bendigo East, Victoria) and GavacTM (Heber Biotec 
S.A., Havana, Cuba) are two Bm86-based vaccine products that 
were developed in the 1990s in Australia and Cuba, respectively 
(DE LA FUENTE et al., 2007). Bm86 is a glycoprotein isolated 
from R. (B.) microplus that appears to be located predominantly 
in tick gut digest cell membranes (GOUGH; KEMP, 1993). The 
R. (B.) microplus bm86 gene is expressed in eggs a few days after 
oviposition, unfed and blood-fed larvae, nymphs, and male and 
female adults (NIJHOF et al., 2009). Additionally, Bm86 has 
been showed to be expressed in the ovaries of partially engorged 
adult females and silencing experiments revealed that Bm86 
plays a role during the feeding period and blood digestion in R. 
(B.) microplus females fed on cattle acutely infected with Babesia 
bovis (BASTOS et al., 2010). There is a direct correlation between 
polyclonal anti-Bm86 antibody production and protection against 
R. (B.) microplus infestation in immunized cattle. Anti-Bm86 
antibodies apparently bind to the surface of epithelial cells in 
the tick’s intestine and disrupt endocytosis thereby causing cell 
lysis and reducing reproductive efficiency in engorged females 
(RIDING et al., 1994; WILLADSEN, 1997). The role of Bm86 
in endocytosis was questioned by Nijhof et al. (2009) because its 
level of expression did not increase during blood uptake.
A pen trial conducted in Mato Grosso do Sul, Brazil, with 
TickGardPLUS and GavacTM using the Campo Grande strain of 
R. (B.) microplus yielded 46.4% and 49.2% efficacy, respectively 
(ANDREOTTI, 2006). These results varied from those previously 
reported for both the anti-R. (B.) microplus vaccine products in 
other parts of the world. The level of efficacy reported for vaccines 
containing a recombinant form of Bm86 varies according to, among 
other factors, the expression system used for vaccine production, 
characteristics of the tick population targeted, and host factors 
(DE LA FUENTE et al., 1999; PATARROYO et al., 2002; 
RAND et al., 1989; RODRÍGUEZ et al., 1995; SITTE et al., 
2002; ANDREOTTI et al., 2008; PARIZI et al., 2009). It has been 
postulated that sequence variation in the bm86 locus is associated 
with low susceptibility of certain R. (B.) microplus populations 
infesting cattle immunized with commercial Bm86-based vaccines 
(GARCÍA-GARCÍA et al., 1999, 2000).
The degree to which sequence variations correlates with the level 
of Bm86-based vaccine efficacy remains to be fully understood. 
Based on polymorphism analysis of the bm86 gene in South 
American strains of R. (B.) microplus, Sossai et al. (2005) suggested 
that geographic isolation is not the sole determinant of genomic 
variation. It has been suggested that diversity greater than 3% in 
amino acid sequence between the recombinant antigen and native 
Bm86 protein in target tick populations results in vaccination 
inefficiencies (GARCÍA-GARCÍA et al., 1999). The similarity 
between deduced protein sequences for Bm86 from the Campo 
Grande strain and the recombinant antigen used in the commercial 
vaccines was 96.5% (ANDREOTTI et al., 2008). Thus, using 
the recombinant Bm86-Campo Grande (rBm86-CG) protein 
as antigen for immunization could yield greater vaccine efficacy 
against R. (B.) microplus infesting cattle in Mato Grosso do Sul.
Of the 205 million head of cattle in the national herd reported 
for 2009, 13.9% was raised in Mato Grosso do Sul (IBGE, 2011). 
The evolution of resistance to commercially available chemical 
acaricides is a constant challenge for producers in the state and it 
is a major driver for research and development of novel strategies 
to control R. (B.) microplus so cattle can be raised sustainably 
(ANDREOTTI et al., 2011). We produced the recombinant 
version of Bm86-CG using the Pichia pastoris expression system 
to test the hypothesis that recombinant Bm86 from a local strain 
would enhance protection against R. (B.) microplus infesting 
immunized cattle in Mato Grosso do Sul state. Here, we report 
the results of a pen immunization trial with the recombinant 
Bm86-CG antigen.
Material and Methods
1. Ticks
Rhipicephalus (B.) microplus used in the study were obtained 
from a laboratory colony maintained at EMBRAPA Beef Cattle. 
These ticks were collected originally from infested cattle in Campo 
Grande - MS, Brazil. Tick larvae were fed on cattle and collected 
as adults after repletion to allow for oviposition and hatching in 
humidity chambers at 28 °C and 95% relative humidity. Larvae 
were used for infestation 18 days after hatching.
2. DNA manipulations
The entire 1825-bp DNA fragment corresponding to Bm86-CG 
(GenBank accession no: EU352677.1) (ANDREOTTI et al., 
2008) was amplified by PCR using primers BmCG-EcoRI-F1 
(CGGAATTCTCATCCATTTGCTC) and BmCG-KpnI-R2 
(TGGAAAGTCAAGTGCGGTACCCC) in a Mastercycler Personal 
thermal cycler (Eppendorf, Germany) using Platinum® Taq DNA 
Polymerase High Fidelity and cloned into the pPICZαA vector 
(Invitrogen). Insertion was confirmed by subjecting plasmid to 
PCR with 5’AOX1 and 3’AOX1 primers that flank the multiple 
cloning site in this plasmid. The resulting plasmid was termed 
pPICZαA-BmCG.
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Pichia pastoris was transformed by electroporation 
(MicroPulser, Bio-rad, USA) according to manufacturer’s 
instructions (INTROGEN, 2009). Briefly, an 80 µL aliquot of 
electrocompetent P. pastoris X33 strain was transformed using 
10 µg of pPICZαA-BmCG linearized with SacI, by applying one 
20 kV pulse during 5 ms. The recombinant cells were selected on 
YPDS plates containing ZeocinTM (1% yeast extract; 2% peptone; 
2% dextrose; 1 M sorbitol; 2% agar; 100 µg/mL Zeocin).
Genomic DNA was extracted from Pichia clones using the 
glass bead disruption method. A 1 mL pellet of culture was 
resuspended with 150 µL of STES (2.42% Tris base; 2.92% 
sodium chloride; 0.1% SDS; 0.372% EDTA; pH 7.6) in a 1.5 mL 
microtube. Fifty µL of glass beads (425-600 µm) and 150 µL of 
phenol:chloroform:isoamyl alcohol (12:12:1 v/v) was added and 
the mixture vortexed for 1 minute and centrifuged at 13,000 g 
for 5 minutes. The supernatant was precipitated with potassium 
acetate, the pellet recovered and rinsed with 70% ethanol, and 
the air-dried DNA resuspended in sterile ultrapure water. DNA 
was quantified using a NanoDrop 2000c Spectrophotometer 
(Thermo Scientific, USA) and stored at –20 °C.
3. Production of polyclonal antibodies and collection of 
murine serum samples
Polyclonal sera against GavacTM and TickGardPLUS, R. (B.) 
microplus larval extract, and rBm86-CG were produced using 
BALB/c mice. To obtain the larval extract, 8 g of larvae were 
frozen at –20 °C, macerated using a mortar and pestle, and 
150 mM Tris-HCl at pH 7.4 added to a final volume of 8 mL. The 
eluted extract was sonicated with two 10 seconds pulses at 60% 
amplitude and another four 10 seconds pulses at 20%. The final 
content was syringe-filtered (0.22 µm) and stored at –20 °C. The 
larval extract was quantified and 3 mg of total protein diluted in 
15 mL of 150-mM Tris-HCl at pH 7.4 and emulsified in 15 mL of 
Freund’s complete adjuvant, which yielded 30 mL of larval extract 
emulsion for immunization. The rBm86-CG vaccine formulation 
was prepared with 500 µg of rBm86-CG protein resuspended in 
5 mL of 150 mM Tris-HCl at pH 7.4, and emulsified with 5 mL 
of complete Freund’s adjuvant. Twenty-four female BALB/c mice 
were separated into four groups of six animals. Each group received 
one of four vaccines at a concentration of 50 µg.mL–1 (GavacTM, 
TickGardPLUS, or rBm86-CG), or 1,000 µg.mL–1 (larval extract 
formulation), for each dose of 100 uL for all doses inoculated. 
Three intramuscular doses were applied at 21-day intervals. Serum 
samples were collected 21 days after the mice received the last 
immunization.
4. Screening of P. pastoris transformants by dot blotting
Each clone was subcultured in 5 mL of BMGY medium 
(1% yeast extract; 2% peptone; 100 mM potassium phosphate at 
pH 6.0; 1.34% YNB; 4 × 10–5% biotin; 1% glycerol) and incubated 
in an orbital shaker set at 220 rpm and 30 °C along with negative 
controls. After 24 hours of incubation, cultures were centrifuged 
at 1500 g for 5 minutes, the supernatant was discarded, and 
the cells resuspended in 5 mL of BMMY (1% yeast extract; 2% 
peptone; 100 mM potassium phosphate at pH 6.0; 1.34% YNB; 
4 × 10–5% biotin; 0.5% methanol). The cultures were returned 
to the shaker for another 4 days. Each culture was supplemented 
with methanol every 24 hours to a final volume of 0.5%. The 
cultures were eventually centrifuged and the supernatants treated 
with 1 mM PMSF for collection in 2 mL microtubes that were 
stored at –20 °C.
A PVDF membrane was washed 10 s in methanol and then 
5 min in sterile ultrapure water. A 5 µL aliquot of each selected 
clone’s supernatant was applied to the pretreated PVDF membrane 
and dried in an oven at 30 °C. Five µL aliquots of GavacTM and 
Tick GardPLUS were used as positive controls on the membranes. 
The membrane was blocked using phosphate buffered saline 
(PBS) containing 5% nonfat dry milk with stirring for 1 hour 
at 30 °C, and subsequently washed twice (5 minutes each time) 
with PBS-T (PBS plus 0.1% Tween 80, pH 7.4). Each membrane 
was then stirred for 1 hour at 30 °C in the presence of polyclonal 
antibodies from the mice vaccinated with GavacTM or TickGardPLUS 
diluted 1:150 in PBS. The membranes were then subjected to 
three additional washes with PBS-T followed by incubation 
with peroxidase-conjugated rabbit anti-mouse IgG secondary 
antibody (Sigma-Aldrich, USA) diluted 1:1000 in PBS-T. The 
process was completed by three additional washes with PBS-T 
and incubation of the membranes in 5 mL of developing solution 
(0.5% diaminobenzidine; 0.075% urea) until coloration was 
observed, which was followed by washing in sterile ultrapure water. 
Photos were taken of the fully processed membranes.
5. Screening for Mut phenotype in P. pastoris transformed 
strains
Phenotypically, recombinant clones can be either Mut+ or 
MutS. The MutS (methanol utilization slow) phenotype results 
from partial loss of activity of alcohol oxidase caused by a 
mutation in the AOX1 (alcohol oxidase 1) gene. Despite this 
mutation, the AOX2 gene is still functional. The result is slow 
growth in methanol by comparison with growth rates observed 
in Mut+ strains. Both classes can be produced by the X33 strain. 
For genotypic analysis of the phenotype under investigation, 
DNA extracted from each clone and DNA from GS115 (Mut+) 
and GS115/albumin (Muts) were subjected to PCR using two 
pairs of primers (3’AOX1 with 5’AOX1, and 3’AOX1 with 
α-Factor) followed by molecular characterization according to 
conditions set forth by the manufacturer. PCR products from 
genomic DNA for each clone (Mut+ and MutS) were sequenced 
with primers designed for the PAOX1 promoter. These sequences 
and Bm86-CG sequence data were compared using ClustalW 
software for sequence alignment.
6. Production of rBm86-CG
For rBm86-CG expression, one colony each from Mut+ and 
Muts clones was plated and isolated, inoculated into a 500 mL 
Erlenmeyer flask containing 25 mL of BMGY medium, and 
incubated overnight in an orbital shaker (220 rpm) at 30 °C until 
reaching OD600 nm = 4, which took 16-18 hours. The cultures 
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were subsequently centrifuged at 1500 g for 5 minutes at room 
temperature and the supernatants discarded. Precipitates of the 
Mut+ clone and the negative X33 were resuspended with ~200 mL 
of BMMY medium to an OD600 nm = 1.0. Each culture was 
supplemented with methanol every 24 hours to a final volume 
of 1%, with a total induction period of 96 hours. Precipitates of 
the MutS clone and a GS115/Albumin clone were resuspended 
in 250 mL of BMGY medium and incubated overnight. These 
cultures were centrifuged again, resuspended in 200 mL of 
BMMY medium, and incubated. Induction was maintained by 
supplementation with methanol every 24 hours to a final volume of 
0.5%, for 96 hours. After this induction period, the cultures were 
centrifuged at 3,300 g at 4 °C for 5 minutes, and the supernatants 
separated, treated with 1 mM PMSF, and frozen at –20 °C.
7. Purification and quantification of rBm86-CG
Supernatants from the material expressed by Mut+ and MutS 
clones were quantified by the standard curve method with bovine 
serum albumin (BSA) on SDS-PAGE. Fifty µL aliquots of a BSA 
solution (0.5 µg.µL–1) were used as quantification standards in a 
7.5% polyacrylamide gel. Bands formed on the gel were quantified 
by visual inspection and through the use of TotalLab 2.0 software 
(Amersham/Biosciences, United Kingdom), which served to 
estimate the apparent molecular mass of bands.
Twenty-five mL of the Mut+ supernatant was incubated 
for 1 hour with methanol 1:1 (v/v) to precipitate proteins by 
centrifugation (5000 g) for 30 minutes at 4 °C. Proteins pellets 
were eluted by adding denaturing binding buffer (8 M urea, 
20 mM Na3PO4, pH 7.8, 500 mM NaCl). This solution was loaded 
onto a Ni2+ charged Ni-NTA (Qiagen, Hilden, Germany) affinity 
column equilibrated with denaturing binding buffer. The column 
was first washed with denaturing binding buffer followed by five 
washes with denaturing wash buffer (pH 6.0). The rBm86-CG 
protein was eluted in denaturing elution buffer (pH 4.0). The 
purification process was monitored by 10% SDS-PAGE. Eluted 
fractions of high purity were pooled and dialyzed against PBS.
8. rBm86-CG electrophoresis and Western blotting
Fifty µL of supernatant from each of two selected clones 
were mixed with 10 µL of SDS-PAGE buffer separately. These 
samples were incubated for 6 min at 95 °C, left to cool down and 
pipetted (20 µL) on a 7.5% polyacrylamide gel. Electrophoresis 
was run for 1.5 hours at 30 mA in a 2D electrophoresis system. 
Electrophoresis material was used for Western blotting analysis 
with 10 µL of Mut+ supernatant per well. Proteins were blotted 
to a PVDF membrane, pretreated with methanol for 10 seconds 
and sterile ultrapure water for 5 minutes, with a transfer system 
immersed in buffer (0.3% Tris base; 1.44% glycine; 15% methanol; 
pH 8.4) at 100 mA for 2 hours. The membrane was washed 
with PBS, left to dry in a stove at 25 °C for 1 hour, stained with 
Ponceau S solution (0.5% Ponceau S; 1% glacial acetic acid), and 
cut into strips. These strips were stirred and blocked with PBS 
containing 5% nonfat dry milk at 30 °C for 1 hour, washed twice 
with PBS-T for 5 minutes, and incubated with primary antibody 
at 1:150 in PBS at 30 °C for 1 hour. One strip was processed 
for each type of serum: anti-Gavac, anti-TickGard, anti-larval 
extract, and anti-rBm86-CG. Each strip was subsequently stirred, 
and washed twice for 5 minutes with PBS-T, and incubated with 
peroxidase-conjugated rabbit anti-mouse IgG secondary antibody 
(1:1000) in PBS-T at 30 °C for 1 hour. This was followed by 
three additional washes, rinsing in sterile ultrapure water, and 
incubation in development solution (5 mL of Milli-Q water; 
5 mg of diaminobenzidine; 0.75 mg of NH4) until well-defined 
bands appeared on the PVDF membrane.
9. Pen trial
The rBm86-CG protein expressed by P. pastoris was adjuvated 
with Montanide ISA 61 VG (Seppic, Paris) to produce 2 mL 
doses each containing 100 µg of antigen. A controlled pen trial 
was conducted to evaluate the immunogenic and protective 
capacity of the rBm86-CG antigen. One-year old Holstein calves 
were acclimated prior to experimentation and received proper 
veterinary care during the study. Cattle were randomly assigned 
to two groups of six animals each. One group was immunized 
with the rBm86-CG antigen following the protocol described 
below. The other six animals served as the control group and were 
treated as per protocol except that they received 2 mL injections 
of adjuvant alone each time. The protocol of Andreotti (2006) 
was slightly modified so each animal was injected intramuscularly 
at 0, 2 and 4 weeks. Serum samples were taken from each animal 
before immunization and weekly thereafter. Twenty-one days after 
the last injection the animals were challenged with 15,000 R. 
(B.) microplus-CG larvae delivered along their back in three 
applications during a week. Tick collections were performed daily 
once the engorged females started detaching spontaneously from 
the control animals. Tick samples were brought to the laboratory, 
weighed, and incubated at 29 °C and 85% relative humidity until 
egg-laying was complete. Egg masses were weighed and incubated 
to determine hatch rate, i.e. fertility.
10. Bovine serum collection and analysis
Blood samples were obtained from cattle before immunization 
and weekly thereafter. Sera obtained from the blood samples was 
frozen for subsequent ELISA analysis. Serum samples were pooled 
by treatment group for each collection date prior to testing. 
Microtiter plates were coated with 1 mg/mL of rBm86-CG 
antigen in 20 mM carbonate buffer (pH 9.6) overnight at 4 °C. 
The plates were blocked with 2% serum bovine albumin in 
PBST (200 mL) and then washed five times with Na3PO4 buffer 
(PBST, pH 7.4, 0.1% Tween 20). This was followed by incubation 
with test bovine serum diluted to 1:100 in PBST (100 mL) for 
45 minutes at 37 °C and another washing cycle. Then, 50 µL of 
rabbit anti-bovine IgG peroxidase conjugate (Sigma, St. Louis, 
MO), diluted 1:20,000, were added and the plate incubated for 
30 minutes at room temperature followed by washing. The process 
was completed by adding 50 µL of the chromogenic substrate 
O-phenylenediamine (1.0 mM), and the reaction stopped after 
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15 minutes with 100 µL of NaOH (0.2 M). A microplate reader 
was used to assess the results with absorbance set at 490 nm.
11. Statistical and eﬃ  cacy analyses
Vaccination eff ects on tick biology and effi  cacy were determined 
as described by García-García et al. (1999) and Andreotti (2006). 
Briefl y, reduction rates associated with Bm86-CG immunization 
relative to the unvaccinated group were determined for adult female 
ticks (% DT), egg-laying capacity (% DO), and fertility (% DF). 
Vaccine effi  cacy was calculated as 100 × [1 – (CRT × CRO × CRF)], 
where CRT, CRO, and CRF are respectively, the reduction in the 
number of adult female ticks, egg-laying capacity, and fertility. 
Th e Mann–Whitney nonparametric test was used to compare 
biological data and to assess vaccine effi  cacy. Mean antibody levels 
were determined for each group and compared using ANOVA as 
described previously (ANDREOTTI, 2006).
Results
1. Production and characterization of P. pastoris 
strains expressing rBm86-CG
A recombinant plasmid was designed by inserting the Bm86-CG 
protein gene sequence in the multiple cloning site of the pPICZαA 
plasmid, between the EcoR I and Kpn I restriction enzyme sites in 
the multiple cloning polylinker (Figure 1). Th e sequence of the 
insert was confi rmed by sequencing and alignment with Bm86-CG 
gene (GenBank accession no: EU352677.1) with 100% identity. 
Th is sequence was cloned taking into consideration the expression 
cassette controlled by the AOX1 gene promoter. Th e multiple 
cloning site was maintained to precede the Bm86-CG sequence, 
which allows future cloning of other sequences of interest.
2. rBm86-CG protein expression by P. pastoris
Th e Mut+ and Muts clones were selected and induced for 
expression. Total protein yield in the supernatant, which included 
rBm86-CG expressed by the Mut+ and Muts clones, was 870 mg.L–1. 
Analysis of the supernatants on 7.5% SDS-PAGE for protein 
expression revealed bands of approximately 80 kDa. Th e expected 
molecular weight for the rBm86-CG protein expressed in this 
system was of 79.1 kDa, which corresponded to the SDS-PAGE 
band observed (Figure 2).
3. rBm86-CG protein recovery and purifi cation
Following electrophoresis of culture supernatants, recoverable 
levels of rBm86-CG were 62.5 and 32 mg.L–1 for Mut+ and 
Muts, respectively. Nickel column purifi cation followed by SDS 
PAGE revealed a protein with an estimated molecular weight of 
80 kDa (Figure 3).
4. rBm86-CG protein characterization
Th e mouse was used to evaluate immune cross-reactivity 
between rBm86-CG and the native and commercial recombinant 
forms of the protein. Western blot analysis of the rBm86-CG 
Figure 1. Map of plasmid vector pPICZαA-Bm86-CG used to transform P. pastoris expression system. Th e map was created with Vector NTI 
8 software; 5’AOX1 promoter: promoter strongly induced by methanol; Sac I: enzyme used to linearize the plasmid before transformation 
in P. pastoris; Alpha-factor: sequence corresponding of secreted peptide of rBm86-CG; EcoR I: recognition sequencing of the enzyme used 
for cloning of 5’ region; Bm86-CG: bm86-CG sequence inserted in plasmid; Kpn I: recognition sequence of the enzyme used for cloning the 
3’ region; 3’AOX1 Termination: sequence that determines the end of the transcript; Zeo(R): Zeocin™ resistance gene allowing selection of 
transformants in Pichia; pUC origin: Replication origin for Escherichia coli.
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protein performed with serum samples from mice immunized with 
GavacTM, TickGardPLUS, R. (B.) microplus larval extract, and rBmCG 
revealed affi  nity for a protein of approximately 80 kDa. Th ese 
results indicated that the rBmCG protein contained epitopes with 
the potential to protect cattle against R. (B.) microplus infestation.
5. Seroconversion of cattle vaccinated with rBm86-CG
Unlike the control animals, vaccinated cattle developed a 
signifi cant antibody response against rBm86-CG (Figure 4) 
(p < 0.05). Antibody levels peaked 21 days after the third 
immunization. Th e bovine humoral immune response to the 
rBm86-CG antigen showed a negative correlation when compared 
to engorged female tick number production. A decrease in the level 
of rBm86-CG antibodies was noted in immunized cattle one week 
after infestation, which was equivalent to that observed the week 
before ticks were placed on the same animals (Figure 4). Kinetics of 
the antibody response between cattle vaccinated with rBm86-CG 
and animals immunized with GavacTM (RODRÍGUEZ et al., 1994) 
and TickGardPLUS (WILLADSEN et al., 1989) were similar.
6. Immunoprotection
Daily collections of engorged ticks dropping from cattle 
were terminated 15 days after tick detachment commenced. 
Th e dynamics of detachment and egg production showed that 
a signifi cant peak in the number of ticks dropping and weight 
of egg masses occurred on the fourth day (p < 0.05; data not 
shown). Immunization of cattle with rBm86-CG reduced the 
number of adult female ticks on them by 28%. No decrease was 
observed in egg-laying capacity. Fertility was reduced 8% (Table 1). 
Vaccination of cattle with the rBm86-CG antigen aff orded 31% 
effi  cacy against R. (B.) microplus infestation.
Discussion
Th e recombinant form of Bm86 from the CG strain of R. (B.) 
microplus was produced using the P. pastoris expression system to test 
its ability to immunoprotect cattle against tick infestation. Secretion 
of rBm86-CG by P. pastoris through the bioprocess reported here 
simplifi ed purifi cation of the antigen. Th is process enhances recovery 
Figure 2. Expression of rBm86-CG by P. pastoris. SDS-PAGE 7.5% 
analysis of the fraction obtained by nickel chromatography process of 
the culture supernatant for clones Mut+ and Muts. M: BenchMark™ 
Protein Ladder standards for SDS-polyacrylamide gel electrophoresis 
ranging in molecular weight from 10 to 220 kDa. Mut+ and MutS: 
10 µg per well of rBm86-CG expressed in Mut+ and MutS clones.
Figure  3. Western blot of rBm86-CG expressed in clone Mut+. 
Lanes  1: anti-Gavac™ serum; 2: anti-TickGardPLUS serum; 3: 
anti-larval extract serum; 4: anti-rBm86-CG serum; 5: larval extract 
as antigen recognized by bovine serum immunized with rBm86-CG; 
6: Negative control. M: BenchMark™ Protein Ladder standards for 
SDS-polyacrylamide gel electrophoresis ranging in molecular weight 
from 10 to 220 kDa.
Figure 4. Antibody response of cattle vaccinated with rBm86-CG 
antigen. Control animals were injected adjuvant Montanide ISA 61 
VG alone. Antibody titers of immunized cattle are depicted as the 
OD490 nm value of the 1:100 dilution of serum samples that were 
pooled for each day of testing. Arrows indicate the day cattle were 
vaccinated. Tick icon indicates day 51 after the fi rst vaccination, 
which is when cattle were infested.
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and purity of recombinant Bm86 antigens expressed in the yeast 
system for vaccine production (CANALES et al., 2008). Th e specifi c 
humoral immune response in vaccinated cattle detected by ELISA 
confi rmed the immunogenicity of rBm86-CG. Immunoblot results 
revealed that polyclonal antibodies from vaccinated cattle recognized 
a protein in larval extracts with a molecular weight corresponding 
to Bm86, which indicated conformational resemblance between 
rBm86-CG and the native protein form.
Immunoprotection of cattle vaccinated with the experimental 
formulation of rBm86-CG yielded a level of effi  cacy 18% lower 
than that reported with the Bm86-based vaccine Gavac™ against the 
R. (B.) microplus CG strain (ANDREOTTI, 2006). Bioinformatic 
analyses by Andreotti et al. (2008) revealed that the similarity of 
the deduced amino acid sequence between Bm86 from R. (B.) 
microplus CG and the Bm86 antigen in Gavac™ was 96.3%. Th e 
31% effi  cacy attained with rBm86-CG was considerably greater 
than the effi  cacy of Bm86 against a strain of R. (B.) microplus from 
Argentina (GARCÍA-GARCÍA et al., 2000). A link between vaccine 
effi  cacy and sequence variability has been questioned because there 
are factors other than primary amino acid sequence of the antigen 
that infl uence the effi  cacy of a vaccine (WILLADSEN, 2008). Th e 
DNA clone used to produce rBm86-CG included sequences coding 
for 608 of the 650 amino acids in the full bm86 open reading frame. 
Ten of the missing amino acids are located in the N-terminus and 
the rest in the C-terminus of the deduced protein sequence. Th e 
missing amino acids do not appear to contain predicted structural 
features of high immunogenic potential (ANDREOTTI et al., 2008). 
Aspects related to vaccine formulation or host factor polymorphisms 
may have caused the lesser than expected effi  cacy obtained in cattle 
immunized with the rBm86-CG antigen.
It is possible that our experimental vaccine formulation lacked 
a component that could have enhanced the immunogenicity of 
rBm86-CG. Advances in vaccinology have enabled the refi nement of 
adjuvants and other components of antigen formulations. Changes 
in the supply chain required the substitution of Montanide 888 
(from animal source) with Montanide 888 VG (from vegetal source) 
in Gavac™ (SEGURA et al., 2009). Two initial vaccinations with 
Gavacplus elicited a high anti-Bm86 antibody response in naïve 
cattle, which caused similar eff ects in R. (B.) microplus as those 
observed with the use of three doses (VARGAS et al., 2010). Th e 
immunogenicity of the rBm86-CG antigen could be enhanced 
by using other adjuvants. Some bacterial cell wall components 
have been shown to be highly immunogenic. Monophosphoryl 
lipid A, a lipopolysaccharide derivative, was approved for use in 
combination with aluminum hydroxide in a commercial human 
papillomavirus vaccine (MCKEE et al., 2010).
Variation in the immune response between animals can impair 
the development of recombinant and peptide vaccines. Major 
histocompatibility complex (MHC) polymorphisms have been 
shown to aff ect the magnitude of the host immune response to 
vaccination (FELLAY et al., 2011). A single amino acid deletion in 
the antigen recognition site of an MHC class II molecule aff ected 
the response to TickGard (SITTE et al., 2002). Th e observation by 
Andreotti et al. (2008), who suggesting that structural portions of 
rBm86-CG may bind to MHC class I molecules, must still be tested 
experimentally. Consideration of the immunogenetic background 
of cattle requires attention during discovery research eff orts to 
develop the next generation of commercial anti-R. (B.) microplus 
vaccines with an effi  cacy profi le that is consistent across breeds.
Th e effi  cacy obtained with Bm86-based vaccines against R. 
(B.) microplus infesting cattle can range between 10 and 89% 
(WILLADSEN, 2008). Because of their high effi  cacy against 
R. annulatus, the use of Bm86-based vaccines is being explored 
for eradication purposes (MILLER et al., 2012). Scientifi c and 
technological advancements off er the opportunity to develop new 
vaccines against cattle ticks. Existing technology based on the Bm86 
paradigm provides the foundation to develop a multi-antigen vaccine 
with an improved profi le yielding a high level of effi  cacy against 
R. (B.) microplus and R. annulatus. Th e positive impact of tick 
vaccines for cattle has been documented (DE LA FUENTE et al., 
2007). A second generation of vaccine anti-R. (B.) microplus must 
meet strict criteria targeting investment opportunities for R & 
D required by international animal health company expecting to 
commercialize the technology globally (MEAT & LIVESTOCK 
AUSTRALIA LIMITED, 2008). Th e rBm86-CG is an antigen 
that could be used in a polyvalent vaccine as part of an integrated 
program for the control of R. (B.) microplus in the region that 
includes Mato Grosso do Sul state.
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